Egfr-Mutated
Entity.
- Evidence
- 25 documents · 8 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 3 Sept 2026, last seen 5 Oct 2026
- Measured
- 36% of mentions say something specific about it; the rest only name it
- As of
- 8 Oct 2026
Where this comes from
- The ASCO Post · 2026-10-05 · Relapsed or Refractory SCLC Phase I Study of Novel CAR T-Cell Therapy (opens the source in a new tab)
- The ASCO Post · 2026-10-05 · Metastatic PD-L1–High NSCLC Sacituzumab Govitecan/Pembrolizumab (opens the source in a new tab)
- AllSci News · 2026-10-02 · AstraZeneca, Daiichi team with Summit to pair Datroway with ivonescimab in Phase III TNBC push (opens the source in a new tab)
- The ASCO Post · 2026-10-02 · Advanced Lung Cancer Pumitamig Plus Elfetabart Drozuntecan (opens the source in a new tab)
- The ASCO Post · 2026-09-30 · Targeting B7-H3 in Second-Line SCLC Treatment Novel ADCs (opens the source in a new tab)
- Fierce Pharma · 2026-09-30 · Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge (opens the source in a new tab)
- AllSci News · 2026-09-30 · AstraZeneca seeks FDA approval for HutchMed's Orpathys plus Tagrisso in MET-driven lung cancer (opens the source in a new tab)
- AllSci News · 2026-09-30 · AstraZeneca invests USD 2b in Summit to advance ivonescimab-ADC combination trials (opens the source in a new tab)
- The ASCO Post · 2026-09-29 · Mobile Lung CT Screening in Resource-Limited Settings BRELT3 (opens the source in a new tab)
- The ASCO Post · 2026-09-18 · Metastatic EGFR-Mutated NSCLC Global Study of Izalontamab Brenitecan (opens the source in a new tab)
- The ASCO Post · 2026-09-16 · Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC (opens the source in a new tab)
- PR Newswire · 2026-09-12 · SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026 (opens the source in a new tab)